Association Between Alu Insertion/Deletion Polymorphism in Intron 8 of Human Tissue Plasminogen Activator Gene (PLAT) and Risk of Age-Related Macular Degeneration
PLAT and AMD
Abstract
Background/Aim: Age-related macular degeneration (AMD) is major reason of blindness in human. Plasminogen is converted to plasmin by tissue plasminogen activator protein (PLAT, formerly known as TPA). A polymorphism in intron 8 of PLAT gene has been reported, either with (insertion) or without (deletion) a 311 bp Alu sequence. This polymorphism is associated with plasma levels of glycoprotein t-PA. t-PA is expressed in the retina and is involved in the development of the eye. It can be hypothesised that the PLAT polymorphism may be correlated with AMD. Therefore, the current study was conducted.
Methods: A total of 121 AMD patients and 108 healthy subjects were included in the study. Genotyping was performed by PCR. The strength of the association between AMD and polymorphism was expressed by estimating the odds ratio (OR).
Results: There was a significant relationship between the Del/Del genotype and susceptibility to AMD (OR = 2.25, 95 % CI = 1.07-4.69, p = 0.031). After adjusting for various factors such as age, smoking habit and workplace, a similar relationship was obtained (OR = 2.51, 95 % CI = 1.01-6.23, p = 0.049).
Conclusions: The homozygosity of the Del allele was found to increase the susceptibility to AMD. This polymorphism may contribute to the risk of AMD in population.
References
1. Katta S, Kaur I, Chakrabarti S. The molecular genetic basis of age-related macular degeneration: an overview. J Genet 2009;88:425-49.
2. Lijnen HR, Collen D. Mechanisms of physiological fibrinolysis. Baillieres Clin Haematol 1995;8:277-90.
3. 3Ludwig M, Wohn KD, Schleuning WD, Olek K. Allelic dimorphism in the human tissue-type plasminogen activator (TPA) gene as a result of an Alu insertion/deletion event. Hum Genet 1992;88:388–92.
4. Batzer MA, Deininger PL. Alu repeats and human genomic diversity. Nat Rev Genet 2002;3:370–9.
5. Jern C, Ladenvall P, Wall U, Jern S. Gene polymorphism of t-PA is associated with forearm vascular release rate of t-PA. Arterioscler Thromb Vasc Boil 1999;19:454–9.
6. Cho HY, Park HS, Ahn EH, Ko EJ, Park HW, Kim YR, et al. Association of polymorphisms in plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA), and renin (REN) with recurrent pregnancy loss in Korean women. J Pers Med 2021;11(12):1378. doi: 10.3390/jpm11121378.
7. Yasin SR, AlHawari HH, Alassaf AA, Khadra MM, Al-Mazaydeh ZA, Al-Emerieen AF, et al. Alu DNA polymorphism of human tissue plasminogen activator (tPA) gene in diabetic Jordanian patients. Iran Biomed J 2019;23(6):423-8.
8. van der Bom JG, de Knijff P, Haverkate F, Bots ML, Meijer P, de Jong PT, et al. Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study. Circulation 1997;95(12):2623-7.
9. Bordbar M, Saadat M. Association between 15 insertion/deletion genetic polymorphisms and risk of schizophrenia using pooled samples. EXCLI J 2023;22:310-4.
10. Collinge JE, Simirskii VN, Duncan MK. Expression of tissue plasminogen activator during eye development. Exp Eye Res 2005;81(1):90-6.
11. Kalteh S, Saadat M. Lack of association between three common genetic variations of XPC and susceptibility to age-related macular degeneration, a preliminary study. Egypt J Med Hum Genet 2020;21:18. doi: 10.1186/s43042-020-00060-w.
12. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989 Apr 11;17(7):2503-16.
13. Valle-Garay E, Montes AH, Corte JR, Meana A, Fierer J, Asensi V. tPA Alu (I/D) polymorphism associates with bacterial osteomyelitis. J Infect Dis 2013;208:218-23.
14. Willeford KT, Rapp J. Smoking and age-related macular degeneration: biochemical mechanisms and patient support. Optom Vis Sci 2012;89:1662-6.
15. Modenese A, Gobba F. Macular degeneration and occupational risk factors: a systematic review. Int Arch Occup Environ Health 2019;92:1-11.
16. Ghazi NG, Noureddine B, Haddad RS, Jurdi FA, Bashshur ZF. Intravitreal tissue plasminogen activator in the management of central retinal vein occlusion. Retina 2003;23:780–4.
17. Schulze SD, Hesse L. Tissue plasminogen activator plus gas injection in patients with subretinal hemorrhage caused by age-related macular degeneration: predictive variables for visual outcome. Graefes Arch Clin Exp Ophthalmol 2002;240:717–20.
18. He X, Cao W, Wang Z, Zhang N, Xu K, Yu L, et al. Efficacy evaluation of tissue plasminogen activator with anti-vascular endothelial growth factor drugs for submacular hemorrhage treatment: A meta-analysis. J Clin Med 2023;12(3):1035. doi: 10.3390/jcm12031035.
19. Ali Said Y, Dewilde E, Stalmans P. Visual outcome after vitrectomy with subretinal tPA injection to treat submacular hemorrhage secondary to age-related macular degeneration or macroaneurysm. J Ophthalmol 2021;2021:3160963. doi: 10.1155/2021/3160963.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).